중등증 이상의 소아 아토피피부염에서 재조합 IFN-γ의 장기적 효과에 대한 연구
Long-term Effect of Recombinant Interferon-Gamma on Moderate and Severe Atopic Dermatitis in Childhood
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose:A number of studies on the treatment of atopic dermatitis have focused on the therapeutic effects of interferon-gamma (IFN-γ) in patients with severe atopic dermatitis, although therapeutic protocols such as duration and dosage of recombinant IFN-γ were different among studies. The beneficial effects of IFN-γ have probably been attributed mainly to its immune modulating effect on the expression of several immunologic mediators although the mechanism of action of IFN-γ therapy in atopic dermatitis is not clear. Objective:The purpose of the present study was to evaluate the therapeutic effect of recombinant IFN-γ on moderate to severe atopic dermatitis with changes in immunologic markers such as IgE level and eosionophil cationic protein (ECP). Methods:Thirty children with moderate to severe atopic dermatitis were selected for the treatment with recombinant IFN-γ, and 10 children with atopic dermatitis were recruited for the controls without IFN-γ treatment. They were followed up every 4 weeks for 3 months after IFN-γ treatment. We evaluated the SCORAD index and immunologic markers including serum IgE and ECP and total eosinophil and neutrophil counts. Results:Significant clinical improvement in reduced SCORAD index was observed 12 weeks after treatment with regimen of recombinant IFN-γ. This clinical outcome was correlated more with changes in eosinophil counts and ECP levels than with those in serum IgE levels. Conclusions:The efficacy of recombinant human IFN-γ therapy for children with moderate to severe atopic dermatitis was maintained without serious side effects for 6 months after final injection of recombinant IFN-γ. Recombinant IFN-γ therapy corrected cellular immune deficits, but not humoral immune defects in patients with atopic dermatitis.
Abstract
Purpose:A number of studies on the treatment of atopic dermatitis have focused on the therapeutic effects of interferon-gamma (IFN-γ) in patients with severe atopic dermatitis, although therapeutic protocols such as duration and dosage of recombinant IFN-γ were different among studies. The beneficial effects of IFN-γ have probably been attributed mainly to its immune modulating effect on the expression of several immunologic mediators although the mechanism of action of IFN-γ therapy in atopic dermatitis is not clear. Objective:The purpose of the present study was to evaluate the therapeutic effect of recombinant IFN-γ on moderate to severe atopic dermatitis with changes in immunologic markers such as IgE level and eosionophil cationic protein (ECP). Methods:Thirty children with moderate to severe atopic dermatitis were selected for the treatment with recombinant IFN-γ, and 10 children with atopic dermatitis were recruited for the controls without IFN-γ treatment. They were followed up every 4 weeks for 3 months after IFN-γ treatment. We evaluated the SCORAD index and immunologic markers including serum IgE and ECP and total eosinophil and neutrophil counts. Results:Significant clinical improvement in reduced SCORAD index was observed 12 weeks after treatment with regimen of recombinant IFN-γ. This clinical outcome was correlated more with changes in eosinophil counts and ECP levels than with those in serum IgE levels. Conclusions:The efficacy of recombinant human IFN-γ therapy for children with moderate to severe atopic dermatitis was maintained without serious side effects for 6 months after final injection of recombinant IFN-γ. Recombinant IFN-γ therapy corrected cellular immune deficits, but not humoral immune defects in patients with atopic dermatitis.
참고문헌 (28)
- Cooper KD, "Atopic dermatitis. Recent trends in pathogenesis and therapy", J Invest Dermatol, 102, pp.128~137 (1994)
- Bruijnzeel-Koomen CAFM, "New aspects in the pathogenesis of atopic dermatitis", Acta Derm Venereol (Stockh), 144, pp.58~63 (1989)
- Eigenmann P, "Diagnosis of allergy syndromes: do symptoms always mean allergy?", Allergy, 60, pp.6~9 (2005)
- Bardana EJ Jr, "Immunoglobulin E- (IgE) and non-IgE-mediated reactions in the pathogenesis of atopic eczema", dermatitis syndrome (AEDS), 2004, pp.59, 25~29
- Gruner S, "The influence of interferon-gamma and interleukin-4 on IgE production in B-lymphocytes of patients with atopic dermatitis", Acta Derm Venereol (Stockh), 71, pp.484~487 (1990)
- Renz H, "Enhanced IL-4 production and IL-4 receptor expression in atopic dermatitis and their modulation by interferon-gamma", J Invest Dermatol, 99, pp.403~408 (1992)
- Reinhold U, "Evidence that defective interferon gamma production in atopic dermatitis patients is due to intrinsic abnormalities", Clin Exp Immunol, 79, pp.374~379 (1990)
- Tang M, "IL-4 and interferon-gamma production in children with atopic disease", Clin Exp Immunol, 92, pp.120~124 (1993)
- Grassegger A, "Significance of the cytokine interferon gamma in clinical dermatology", Clin Exp Dermatol, 29, pp.584~588 (2004)
- Parkin JM, "Atopic manifestations in the acquired immune deficiency syndrome: response to recombinant interferon gamma", Br Med J, 294, pp.1185~1186 (1987)
- Hanifin JM, "Recombinant interferon gamma therapy for atopic dermatitis", J Am Acad Derm, 28, pp.189~196 (1993)
- GW Noh, "Immunotherapy with systemic interferon-γ in severe atopic dermatitis", Pediater Allergy Respir Dis(Korea), 7, pp.239~247 (1997)
- Hanifin JM, "Standardized grading of subject for clinical research studies in atopic dermatitis", Acta Derm Venreral (Stockh), 144, pp.28~30 (1989)
- European Task Force on Atopic Dermatitis, "Severity scoring of atopic dermatitis: the SCORAD index", Dermatology, 186, pp.23~31 (1993)
- Lacour M, "Acute infections in atopic dermatitis. a clue for a pathogenesis role for a Th1", Th2 imbalance, 1994, pp.188, 25~257
- Del Prete G, "Human Th1 and Th2 lymphocytes. their role in the pathophysiology of atopy", Allergy, 47, pp.450~455 (1992)
- Chan SC, "Abnormal IL-4 gene expression by atopic dermatitis. T lymphocyte is reflected in altered nuclear protein interaction with IL-4 transcriptional regulatory element", J Invest Dermatol, 106, pp.1131~1136 (1996)
- Pung YH, "Use of interferons in atopic (IgE-mediated) disease", Ann Allergy, 71, pp.234~238 (1993)
- Jujo K, "Decreased interferon gamma and interleukin-4 production in atopic dermatitis promotes IgE synthesis", J Allergy Clin Immunol, 90, pp.323~331 (1992)
- Teramato T, "Serum IgE level is negative correlated with the ability of peripheral mononuclear cells to produce interferon gamma: evidence of reduced expression of IFN-γ mRNA in atopic patients", Clin Exp Allergy, 28, pp.74~82 (1998)
- Yancey KB, "Interferon : Status in treatment of skin disease", J Am Acad Dermatol, 3, pp.585~595 (1980)
- Stadler R, "Interferon in dermatology", J Am Acad Dermatol, 20, pp.650~656 (1989)
- Knop J, "Immunologic effect of interferon", J Invest Dermatol, 95, pp.S72~S74 (1990)
- Gresser I, "Biologic effects of interferons", J Invest Dermatol, 95, pp.S66~S71 (1990)
- Seth R, "Long-term effectiveness and safety of recombinant human interferon gamma therapy for atopic dermatitis despite unchanged serum IgE levels", Arch Dermatol, 134, pp.799~804 (1998)
- SH Jung, "Systemic Interferon-Gamma Therapy for atopic dermatitis", Pediater Allergy Respir Dis(Korea), 9, pp.200~209 (1999)
- Stary G, "Dendritic cells in atopic dermatitis: expression of FcepsilonRI on two distinct inflammation-associated subsets", Int Arch Allergy Immunol, 138, pp.278~290 (2005)
- Nichioka K, "Gamma-interferon therapy for severe case of atopic dermatitis of the adult type", J Dermatol, 22, pp.181~185 (1995)